Sensex

up-green-arrow

Nifty

up-green-arrow

USDINR

down-red-arrow

GBPINR

down-red-arrow

EURINR

down-red-arrow

Company News

Aurobindo Pharma Ltd
CuraTeQ Biologics receives European marketing authorization for biosimilar Dazublys™
Jul 02,2025
CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma, has obtained marketing authorization from the European Commission for Dazublys™, its trastuzumab biosimilar version. Earlier in April 2025, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Dazublys™, recommending its marketing authorization. This is CuraTeQ's third biosimilar to be approved by EMA after the approval of Dyrupeg™ in April 2025 and Zefylti™ in February 2025, and the fourth overall in the EU, alongside the approval of Bevqolva™ by the UK's MHRA in December 2024.

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

A Muthoot M George Enterprise